论文部分内容阅读
β-受体阻滞剂 (βB)在心血管疾病的治疗中已应用多年 ,但在具体的实施、适应症的选择、临床疗效的评估方面还存在不少分歧。近几年国内外进行了许多大型临床试验 ,取得了明显进展。1 在急性心肌梗死中的应用βB主要是通过竞争性抑制β受体活性而引起一系列药理效应 ,从而使心
β-blockers (βB) have been used in the treatment of cardiovascular disease for many years, but there are still many differences in the specific implementation, the choice of indications and the assessment of clinical efficacy. In recent years, many large-scale clinical trials have been carried out at home and abroad and significant progress has been made. 1 in the application of acute myocardial infarction βB mainly by competitive inhibition of β-receptor activity caused a series of pharmacological effects, so that the heart